{"id":"b2e9059b8a96","type":"article","url":"https://hartvaat.nl/2026/02/27/gerichte-immunotherapie-bij-nierziekten-b-cel-targeting-en-car-t/","title":"Gerichte immunotherapie bij nierziekten: B-cel-targeting en CAR-T","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00145-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00145-6/fulltext","authors":["Johanna T. Kurzhagen","William Laqua","Georg Schett","Ricardo Grieshaber-Bouyer","Hamid Rabb","Sanjeev Noel","Mario Schiffer"],"significance":5,"published":"2026-04-04","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This Kidney International review discusses emerging targeted immunotherapies for kidney disease, including CAR-T cell therapy and T-cell engagers directed against B cells. Initial results in treatment-resistant lupus nephritis are promising and may extend to other autoimmune kidney diseases.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit overzichtsartikel in Kidney International bespreekt de opkomst van gerichte immunotherapie bij nierziekten, waaronder CAR-T-celtherapie en T-cel-engagers gericht op B-cellen. De eerste resultaten bij therapieresistente SLE-nefritis zijn veelbelovend en kunnen relevant worden voor andere auto-immuun nierziekten.","abstract_original":"Recent advances in immunotherapy targeting B cells have ushered in a new era for disease treatment. The effectiveness of targeted approaches such as T-cell engagers or B cell–directed chimeric antigen receptor (CAR)-T-cell therapy in treating autoimmune diseases has been demonstrated so far only in uncontrolled, investigator-initiated trials. Several case series in patients with therapy-resistant systemic lupus erythematosus showed efficacy and safety of CD19+ CAR-T cells, showing depletion of autoreactive B cells and full clinical remission."}